Muscle News and Research

RSS

ADM hormone plays a significant role in tubal ectopic pregnancies

Tubal ectopic pregnancy (TEP) is currently the leading cause of pregnancy-related deaths during the first trimester and a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) shows that the hormone adrenomedullin (ADM) may help predict this condition.

3 May 2012

JS Genetics announces availability of XCAT-KS buccal swab test

JS Genetics announces the availability of XCAT-KS, its proprietary buccal swab test for the diagnosis of Klinefelter syndrome (KS) and other male sex chromosome aneuploidies.

3 May 2012

Bladder tests performed on women before SUI surgery may not be necessary

Invasive and costly tests commonly performed on women before surgery for stress urinary incontinence (SUI) may not be necessary, according to researchers at the University of California San Diego, School of Medicine and the Urinary Incontinence Treatment Network. The study, supported by the National Institutes of Health (NIH), will be released online May 2 by the New England Journal of Medicine.

3 May 2012

Hypothalamic neuropeptide changes cause obesity in low-birth-weight babies

It seems improbable that a baby born underweight would be prone to obesity, but it is well documented that these children tend to put on weight in youth if they're allowed free access to calories. Now, researchers believe they understand why this happens.

3 May 2012

Ligand first quarter total revenues increase to $5.6 million

Ligand Pharmaceuticals Incorporated today reported financial results for the first quarter ended March 31, 2012, and provided an operating forecast and program updates.

3 May 2012

PRDM16 transcription co-factor plays a critical role in development of embryonic palate

In the United States, a baby is born with a facial cleft every hour, of every day of the year! Such birth defects result from both gene mutations and environmental insults. PRDM16 is a transcription factor originally described as being aberrantly activated in specific types of leukemia's, and more recently as a master regulator of brown adipose tissue differentiation.

3 May 2012

Expression of tyrosine kinases may limit effectiveness of agents against sarcomas

To better understand the signaling pathways active in sarcomas, researchers at Moffitt Cancer Center used state-of-the-art mass spectrometry-based proteomics to characterize a family of protein enzymes that act as "on" or "off" switches important in the biology of cancer. The tyrosine kinases they identified, the researchers said, could act as "drivers" for the growth and survival of sarcomas.

2 May 2012

Rigel first quarter net loss increases to $23.2 million

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2012.

2 May 2012

Diagnosis of neonatal abstinence syndrome triples between 2000 and 2009

About one baby is born every hour addicted to opiate drugs in the United States, according to new research from University of Michigan physicians.

2 May 2012

Ultragenyx reports results from UX001 Phase 1 study on HIBM

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration

2 May 2012

Sanofi Pasteur announces new quadrivalent influenza vaccine Phase III pediatric data

Sanofi Pasteur, the vaccines division of Sanofi, announced today new Phase III data for its investigational quadrivalent influenza vaccine (QIV) in children 6 months through 8 years of age.

2 May 2012

SCPC accredits Porter Adventist Hospital as Chest Pain Center

The Society of Chest Pain Centers (SCPC) recently awarded Porter Adventist Hospital full accreditation status as a Chest Pain Center.

2 May 2012

Chemo-radiotherapy combination a viable alternative for frail bladder cancer patients

Bladder cancer patients given low doses of chemotherapy combined with radiotherapy were nearly 50 per cent less likely to relapse with the most lethal form of the disease compared to those given radiotherapy alone, a major trial funded by Cancer Research UK shows.

2 May 2012

Tyrosine kinases could act as drivers for growth and survival of sarcomas

2 May 2012

Interferon linked with increased risk of depression in HCV patients

There's a high rate of depression among patients with hepatitis C, but a standard treatment for the disease includes a drug, interferon, that can cause depression.

2 May 2012

Reducing levels of SUN1 protein increases life span of mice with progeria, heart disease

Scientists have discovered that they can dramatically increase the life span of mice with progeria (premature ageing disease) and heart disease (caused by Emery-Dreifuss muscular dystrophy) by reducing levels of a protein called SUN1.

30 Apr 2012

FDA approves Levaquin for plague

The U.S. Food and Drug Administration today approved Levaquin (levofloxacin) to treat patients with plague, a rare and potentially deadly bacterial infection. The agency also approved the drug to reduce the risk of getting plague after exposure to Yersinia pestis, the bacterium that causes the disease.

30 Apr 2012

Novel liquid drug used successfully in a heart attack patient

They did the first procedure of its kind by injecting the dissolvable liquid device into a patient - a Victorian grandmother. The device flows to the damaged heart muscle and helps it repair. The liquid is derived from seaweed and was injected into Pauline Fulton's heart, a fortnight ago, two days after she suffered a major heart attack.

29 Apr 2012

Researchers discover gene for new form of intellectual disability

Researchers at the Centre for Addiction and Mental Health (CAMH) led a study discovering a gene for a new form of intellectual disability, as well as how it likely affects cognitive development by disrupting neuron functioning.

27 Apr 2012

Rochester researcher to continue MS study

A Rochester, New York, researcher will receive a $263,622 grant to continue his study of injury to brain cell connections (synapses) in multiple sclerosis (MS) through the American Brain Foundation (formerly the American Academy of Neurology Foundation) and the National Multiple Sclerosis Society Clinician-Scientist Development Award.

27 Apr 2012